RxDoctor Payments Data

Benjamin Oyefara, MD

Allergy & Immunology · Monroe, LANPI 1285660589

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $916 of the $1,102 with a category attached, or 83.1%. 13 manufacturers reported payments, led by AstraZeneca at 42.8% of the total. That places this record below the midpoint for allergy & immunology clinicians in LA, where the typical reported total is $3,029.

$1,102in general payments, 2019–2025

Across 32 payments — averaging $34.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$471
  • Sanofi$254
  • Regeneron Healthcare Solutions, Inc.$99
  • Sanofi-aventis U.S. LLC$62
  • Pfizer$50
  • Novartis$32
  • plus $133 from 7 others

What the payments were for

  • Food & beverage$91683%
  • Education$18617%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,102 in reported general payments places this provider in the 25th percentile of 62 allergy & immunology providers in Louisiana.

See all allergy & immunology providers in Louisiana

Medicare billing

Part B allowed, 2024
$23,626
Medicare patients
79
Services billed
1,721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$21,183
Spiriva RespimatTiotropium Bromide21$17,021
DuleraMometasone/Formoterol14$4,190
SymbicortBudesonide/Formoterol Fumarate16$3,811
Azelastine Hcl90$1,884
Albuterol Sulfate HfaAlbuterol Sulfate35$1,658
Fluticasone Propionate138$1,647
Ipratropium Bromide32$1,355
Montelukast Sodium142$949
Levocetirizine Dihydrochloride29$497
Triamcinolone Acetonide29$423
Methylprednisolone30$217
Prednisone86$162
Doxepin Hcl12$151
Famotidine11$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Symbicort$471$24,99450 claims
Boehringer IngelheimSpiriva Respimat$15$17,02121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 62 allergy & immunology providers in Louisiana.

Other allergy & immunology in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →